Using CellaVision's application for body fluids, clinical laboratories are now able to analyse and assess cells in spinal fluid, synovial fluid, and pleural fluid
CellaVision, which develops and sells digital morphology products for the routine analysis of blood, widens its product offering to clinical laboratories by launching a new application for the analysis of body fluids, including cerebrospinal, synovial and pleural fluids.
In addition, a new version of the blood application will be launched, now offering a way to digitize an entire slide.
"We see a great demand among our clients for the type of functions that CellaVision can now offer.
"To be able to analyse blood and other body fluids in a safe, efficient, and comfortable way is surely the ideal solution for many laboratories," says Yvonne Martensson, CEO of CellaVision.
"The ability to scan full slides is an additional service offered to laboratories which will give us an opportunity to further evaluate the market needs in other imaging segments, such as pathology and cytology".
The advantages of the new application are the same as those for blood - faster and more standardised results, digital archiving of samples together with patient records, as well as sharing of digital images with experts outside the laboratory.
A new function has been added to software version 2.0 of CellaVision's application for peripheral blood which makes it now possible to capture digital images of any desired area of slides, creating a digital slide.
Although primarily designed for haematology smears, the digitalisation function is also applicable to other types of specimens, for educational purposes.
It gives a useful overview of the sample and allows for discussion between physicians regardless of physical location.
The application for body fluids will be offered as a separate product while the function for digital scanning of samples is included in the company's most recent software version for peripheral blood.
Both functions are available for the CellaVision DM96 analyser and will be commercially available in Europe in the beginning of 2008.
An application to the US Food and Drug Administration (FDA) concerning sales of the body fluids application in the USA will be submitted at the same time.
